在黑色素瘤中探索免疫检查点抑制剂和向治疗的耐药性
Anum Jalil1, Melissa M Donate2, Jane Mattei3
1Department of Medicine, UT Health Science Center San Antonio, San Antonio, TA 78229, USA.
Cancer drug resistance (Alhambra, Calif.)
|November 13, 2024
概括
像免疫疗法这样的黑色素瘤治疗改善了存活率,但耐药性仍然是一个挑战. 了解抵抗机制是开发新疗法的关键,以改善皮肤癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 癌症研究 癌症研究
背景情况:
- 黑色素瘤的发病率有所增加,转移性黑色素瘤在历史上有着不良的预后.
- 免疫疗法和向治疗的最新进展显著提高了转移性黑色素瘤患者的生存率.
- 尽管治疗进展,但大约50%的患者表现出原发性或获得性耐药性,导致复发.
研究的目的:
- 审查免疫治疗和黑色素瘤向治疗的耐药性背后的分子机制.
- 探索旨在克服黑色素瘤耐药性的新型治疗策略.
- 增强对黑色素瘤治疗中复发模式和耐药性因素的理解.
主要方法:
- 关于黑色素瘤治疗耐药性的最近临床试验和研究研究的文献综述.
- 对涉及黑色素瘤治疗耐药性的分子途径和遗传因素的分析.
- 综合当前和新兴的治疗策略,以打击黑色素瘤耐药性.
主要成果:
- 免疫疗法和向治疗改变了黑色素瘤的生存率,超过50%的五年生存率.
- 对这些疗法的初级和二级耐药性机制尚未完全阐明,但涉及到特定的分子途径.
- 几种遗传因素和分子通路与黑色素瘤的治疗耐药性有关.
- 新兴的策略在临床试验中显示出克服耐药性和改善患者结果的希望.
结论:
- 虽然目前的疗法已经改善了黑色素瘤的存活率,但耐药性仍然是一个重大的临床挑战.
- 进一步研究黑色素瘤耐药性的分子基础对于开发更有效的治疗方法至关重要.
- 针对抗药机制的新型治疗策略对于进一步改善黑色素瘤患者的治疗结果至关重要.
相关概念视频
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K